부산대학교 도서관

Background Anti-vascular endothelial growth factor (anti-VEGF) therapy is used for myopic choroidal neovascularization (mCNV). Patchy chorioretinal atrophy (pCRA) enlargement has been reported in mCNV cases associated with vision loss. Our aim was to compare the long-term effectiveness of anti-VEGF therapy alone versus anti-VEGF followed by posterior scleral reinforcement (PSR) in controlling myopic maculopathy in mCNV eyes. Methods We performed a retrospective review of the medical records of 95 high myopia patients (refractive error [greater than or equal to] 6.00 diopters, axial length [greater than or equal to] 26.0 mm) with mCNV. Patients were treated with anti-VEGF alone (group A) or anti-VEGF followed by PSR (group B). The following data were collected: refractive error, best corrected visual acuity (BCVA), ophthalmic fundus examination, ocular coherence tomography and ocular biometry at 12 and 24 months pre- and postoperatively. The primary outcomes were changes in pCRA and BCVA. Results In 26 eyes of 24 patients, the mean pCRA size significantly increased from baseline (0.88 [+ or -] 1.69 mm.sup.2) to 12 months (1.57 [+ or -] 2.32 mm.sup.2, t = 3.249, P = 0.003) and 24 months (2.17 [+ or -] 2.79 mm.sup.2, t = 3.965, P = 0.001) postoperatively. The increase in perilesional pCRA in group B (n = 12) was 98.2% and 94.2% smaller than that in group A (n = 14) at 12 and 24 months (Beta 0.57 [95% CI 0.01, 191 1.13], P = 0.048). In group B, 7 eyes (58.3%) gained more than 2 lines of BCVA compared with only 4 eyes (28.6%) in group A at 24 months. Conclusion Anti-VEGF therapy followed by PSR achieved better outcomes than anti-VEGF therapy alone in controlling the development of myopic maculopathy in mCNV and may constitute a better treatment option by securing a better long-term VA outcome. Keywords: Choroidal neovascularization, Myopic maculopathy, Anti-vascular endothelial growth factor, Posterior scleral reinforcement
Author(s): Meng-Tian Kang[sup.1,2], Ningli Wang[sup.1,2], Wenjun Xu[sup.1], Mayinuer Yusufu[sup.3,4], Wu Liu[sup.1], Jiaxin Tian[sup.1,2] and Yue Qi[sup.1] Introduction Pathologic myopia is the second most common cause of visual impairment in East [...]